Posted by Michael Wonder on 21 May 2026
Bayer’s Kerendia (finerenone) granted priority review of supplemental new drug application by US FDA for treatment of adults with type 1 diabetes and chronic kidney disease
21 May 2026 - Bayer announced today that the US FDA accepted its supplemental new drug application and granted priority review designation for Kerendia (finerenone), which is being investigated for the treatment of adults with type 1 diabetes and chronic kidney disease.
The supplemental new drug application was supported by the Phase 3 FINE-ONE trial, which showed Kerendia significantly reduced urine albumin to creatinine ratio over six months compared with placebo when either are used alongside standard of care for adults with type 1 diabetes and chronic kidney disease.
